ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
Promising new assays and technologies for the diagnosis and management of infectious diseases.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03473119 (Acute Effects of Particulate Matter on Pulmonary Diseases), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acute Effects of Particulate Matter on Pulmonary Diseases: Discovery Its Chemo-signatures
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials.Age and ageing · 2021Pooled it
- Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis.Medicine · 2019Pooled it
- Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.Critical care (London, England) · 2018Pooled it
- Prognostic Utility of Delta-Procalcitonin and Modified Shock Index for Risk Stratification of Sepsis in Acute Care Settings.Journal of community hospital internal medicine perspectives · 2026Article
- Value of Early Kinetics of Procalcitonin with Point-of-Care Test to Predict Postoperative Abscess Following Non-Complicated Acute Appendicitis: A Pilot Study.Medicina (Kaunas, Lithuania) · 2025Article
- Serial Procalcitonin Measurements for Determining Bacterial Infection and Mortality in Cirrhotic Patients With Systemic Inflammatory Response Syndrome.Clinical and translational gastroenterology · 2025Article
- Biomarkers (NLR, PLR, SII) for Frequent COPD Exacerbations: Diagnostic and Clinical Management Implications in a Retrospective Study.International journal of chronic obstructive pulmonary disease · 2025Observational
- Cost-effectiveness of Procalcitonin (PCT) guidance for antibiotics management of adult sepsis patients in the Egyptian context.BMC health services research · 2024Article
- Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.Frontiers in neuroscience · 2024Review
- Serum exosomal microRNA-1258 may as a novel biomarker for the diagnosis of acute exacerbations of chronic obstructive pulmonary disease.Scientific reports · 2023Article
- Biomarkers for risk stratification and antibiotic stewardship in elderly patients.Aging clinical and experimental research · 2023Review
- PROCALCITONIN GUIDED ANTIBIOTIC STEWARDSHIP: A BALKAN EXPERT CONSENSUS STATEMENT.Acta clinica Croatica · 2023Article
- Smart Graphene-Based Electrochemical Nanobiosensor for Clinical Diagnosis: Review.Sensors (Basel, Switzerland) · 2023Review
- Article
- Sphingosine-1-phosphate and CRP as potential combination biomarkers in discrimination of COPD with community-acquired pneumonia and acute exacerbation of COPD.Respiratory research · 2022Observational
- The Prognostic Role of Procalcitonin in Critically Ill Patients Admitted in a Medical Stepdown Unit: A Retrospective Cohort Study.Scientific reports · 2020Observational
- Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis.Infection & chemotherapy · 2020Review
- Role of procalcitonin use in the management of sepsis.Journal of thoracic disease · 2020Review
- Selection of an Optimal Combination Panel to Better Triage COVID-19 Hospitalized Patients.Journal of inflammation research · 2020Article
- Biomarkers of Infection: Are They Useful in the ICU?Seminars in respiratory and critical care medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
In the first decade of the 21st century, we have seen the completion of the human genome project and marked progress in the human microbiome project. The vast amount of data generated from these efforts combined with advances in molecular and biomedical technologies have led to the development of a multitude of assays and technologies that may be useful in the diagnosis and management of infectious diseases. Here, we identify several new assays and technologies that have recently come into clinical use or have potential for clinical use in the near future. The scope of this review is broad and includes topics such as the serum marker procalcitonin, gene expression profiling, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and nucleic acid aptamers. Principles that underlie each assay or technology, their clinical applications, and potential strengths and limitations are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.